The Japan Medical Affairs Summit, Co-Organized by MAPS, PhRMA and JAPhMed is taking place in Tokyo, Japan, June 15-16, 2023. We invite you to HELP SHAPE the future of healthcare in Japan as Medical Affairs continues to make an impact on patient outcomes.
Since its opening in 1987, PhRMAʼs Japan office has actively developed various activities on behalf of its member companies in Japan. We promote activities focused on direct dialogue with all concerned parties such as government officials, doctors and other medical staff, media parties and patient organizations. PhRMA cooperates with the Japan Pharmaceutical Federation, the Japan Pharmaceutical Industry Association, and the European Pharmaceutical Federation to develop activities.
JAPhMed has more than 50 years of history in developing “pharmaceutical medicine” in Japan which is defined as a medical specialty concerned with the discovery, development, evaluation, licensing and monitoring of medicines and the medical aspects of their marketing. Based on our mission: “To promote Pharmaceutical Medicine by enhancing the knowledge, expertise and skills of pharmaceutical professionals and physicians, thus leading to the availability and appropriate use of medicines for the benefit of patients and the society.” JAPhMed operates as the Japanese affiliate of the International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine (IFAPP).
The Medical Affairs Professional Society (MAPS) is the premier non-profit global Medical Affairs organization FOR Medical Affairs professionals BY Medical Affairs professionals across all different levels of experience/specialty. Together with over 10,500 Medical Affairs members from 300+ companies globally, MAPS is transforming the Medical Affairs profession to increase its value to patients, HCPs, industry and society.
MAPS transforms Medical Affairs organizations and Medical Affairs professionals globally by: speaking as the single voice of the Medical Affairs profession; defining the current and future practice of Medical Affairs; being the global community for Medical Affairs professionals; and leveraging collective thought leadership to train the next generation of Medical Affairs leaders.
Station Conference Tokyo
Sapia Tower 5F, 1-7-12 Marunocouchi, Chiyoda-ku
Tokyo 100-0005 Japan +81 3-6888-8080
Simultaneous Translation for English/Japanese is available for the General Session on June 15. Please note that the MSL Workshop on June 16 will be held in Japanese and will not have translation service provided. Please check the Brochure to find more information
9:00 – 9:30: Registration
9:30 – 10:30: The Future of Medical Affairs: How Does Japan Medical Affairs Align with the MAPS 2030 Report?
10:30 – 10:45: Welcome Remarks
10:45 – 11:45: Measuring the Impact of Medical Affairs on Patient Outcomes
11:45 – 13:45: Current Issues and Future Horizons of Industry-Academia Collaboration for Utilization of RWD
13:45 – 14:15: Bento Lunch
14:15 – 16:15: How Can Medical Education Programs Bring More Value to the Medical Environment? Challenges & Future Ideal State
14:15 – 18:15: Current Status and Challenges of Patient Engagement in Japan
18:15 – 19:30: Evening Cocktail Reception
8:30 – 9:00: MSL Workshop Registration
9:00 – 13:00: Unleash the Potential of Medical Science Liaison (MSL) to Maximize the Value of MSL to Patients
13:00: Japan Medical Affairs Summit Ends
All Pricing is in US Dollars
Head of Medical Affairs & Medical Affairs committee Chair
MSD K.K. / PhRMA
Chief Medical Officer & Vice Chairperson, Head of Medical Affairs Committee
Aculys / JAPhMed
Vice President & Region Head Medical, JAPAC & APAC President
Amgen / MAPS
Senior Manager, MSLO Excellence, MO, Medical Affairs Division/MSL Training Curriculum Lead
Alexion Pharma / JAPhMed
MSL / Medical Affairs Committee Working Group 3, Leader
MSD K.K / PhRMA
MSL, Oncology Medical Affairs
Merck BioPharma Co., Ltd.
Director, Immunology and Infectious Diseases Dept., MA Division & Medical Affairs Committee Working Group 2, Leader
Janssen Pharmaceutical K.K. / PhRMA
Director, Head of Policy Department, IMAT & Medical Affairs Committee Working Group 1, Leader
Janssen Pharmaceutical K.K. / PhRMA
Director, Medical Science Liaison Dept. / Medical Affairs Division & Medical Affairs Committee Working Group 3
Janssen Pharmaceutical K.K. / PhRMA
Director / Medical Affairs Lead Autoimmune Diseases Products, Bio-Medicines Japan Drug Development and Medical Affairs & Medical Affairs Committee Working Group 3
Eli Lilly Japan K.K. / PhRMA
Professor, Department of Health Policy Management
Nippon Medical Hospital
Email mgiordano@medicalaffairs.org to secure a sponsorship.
MEDiSTRAVA was created to guide Medical Affairs teams through a period of rapid transformation in technology, evolving healthcare community needs, and growing expectations for therapeutic advances.
Delivering medical value in this new and changing environment requires diverse capabilities and deep expertise that extend beyond the traditional medical affairs role. We bring together specialised teams in strategy, medical excellence, evidence generation, market access, patient engagement and medical analytics to create solutions that are tailored to your needs, and focused on achieving your objectives.
Headquartered in Singapore and with offices throughout Asia-Pacific, MIMS empowers healthcare communities to improve patient outcomes. Through our diverse offerings spanning medical communications, market research, drug information services and multi-channel marketing, and our own HCP platform with more than 2 million subscribers across APAC, we provide tailored solutions to leading pharmaceutical companies and healthcare institutions. Expand your impact with MIMS – the medical communications agency with the widest coverage across APAC.
Ubie is a health tech startup founded in May 2017 by a physician and an engineer with a mission to “guide people to the right medical care with technology”.The company uses AI as its core technology to develop and offer “Ubie Symptom Checker”, which guides people from symptoms to the right medical care, and “Ubie-Medical Navi”, a service for healthcare providers to improve the quality of medical care. We are trying to create a world where everyone has access to the medical care that is right for them.
MAPSはメディカルアフェアーズ組織の進化・発展を目的として運営されている世界的な学会です
ジャパンサミット2023
MAPS、PhRMA、JAPhMed が共催するジャパン メディカル アフェアーズ サミットが、2023 年 6 月 15 ～ 16 日に東京で開催されます。患者の転帰について。
PhRMAの日本オフィスは1987年1月の開設以来、在日加盟企業を代表し様々な活動を積極的に展開しています。行政、医療政策担当者、医師をはじめとする医療従事者、報道関係者、そして患者団体等、関係するすべての団体と直接対話を重視した活動を推進しています。PhRMAは日本製薬団体連合会、日本製薬工業協会、欧州製薬団体連合会と協力して活動を展開しています。
一般財団法人 日本製薬医学会は製薬医学に関わる業務、すなわち、新薬の開発、承認、医薬品の販売、管理・安全対策等において活躍されている産官学のメンバーを中心とした団体です。本学会は1967年1月のMD会を出発点として、既に50年余りの歴史を有しており、2009 年4 月より一般財団法人 日本製薬医学会（The Japanese Association of Pharmaceutical Medicine : JAPhMed）として法人化し現在に至っております。
本学会では、“製薬医学専門家の知識、専門性およびスキルの向上を通して製薬医学を推進し、患者と社会のベネフィットのために医薬品へのアクセスと適正使用へと導くことにある” をミッションとして掲げておりますJAPhMedは国際製薬医学会（IFAPP）の日本支部として運営されています。
The Medical Affairs Professional Society (MAPS) is the premier non-profit global Medical Affairs organization FOR Medical Affairs professionals BY Medical Affairs professionals across all different levels of experience/specialty. Together with over 10,500 Medical Affairs members from 300+ companies globally, MAPS is transforming the Medical Affairs profession to increase its value to patients, HCPs, industry and society.
MAPS transforms Medical Affairs organizations and Medical Affairs professionals globally by: speaking as the single voice of the Medical Affairs profession; defining the current and future practice of Medical Affairs; being the global community for Medical Affairs professionals; and leveraging collective thought leadership to train the next generation of Medical Affairs leaders.
ステーションコンファレンス東京
〒100-0005 東京都千代田区丸の内1-7-12
サピアタワー4〜6F
TEL: 03-6888-8080
アクセス
ＪＲ東京駅日本橋口 直結 / 八重洲北口 徒歩2分
東京メトロ東西線大手町駅B7出口 直結
6 月15 日に開催される一般セッションでは日英同時通訳が利用可能です 6 月16 日に開催されるMSL ワークショップは日本語で実施されます。日英同時
通訳の提供はございませんこと予めご了承ください。
9:00 – 9:30: 参加登録
9:30 – 10:30: The Future of Medical Affairs: How Does Japan Medical Affairs Align with the MAPS 2030 Report?
10:30 – 10:45: 開会の挨拶
10:45 – 11:45: Measuring the Impact of Medical Affairs on Patient Outcomes
11:45 – 13:45: RWD活用における産学連携の現状の課題とこれからの地平
13:45 – 14:15: 昼食（軽食を提供）
14:15 – 16:15: より価値の高いメディカルエデュケーションプログラムを提供するには？課題と今後のあるべき姿
14:15 – 18:15: 日本のおける患者エンゲージメントの現状および課題
18:15 – 19:30: イブニングカクテルレセプション
8:30 – 9:00: MSL Workshopへの参加登録
9:00 – 13:00: MSLの価値最大化にむけて
13:00: Japan Medical Affairs Summitの終了
価格はアメリカドルで表示されています
シニアマネージャー、MSLエクセレンス / MSLトレーニングカリキュラムタスク リード
アレクシオンファーマ合同会社/ 日本製薬医学会
メディカルアフェアーズ本部免疫 ・感染症部部長/ メディカルアフ ェアーズ委員会WG2 リーダー
ヤンセンファーマ株式会社/ 米国研究製薬工業協会
メディカルアフェアーズ本部 メディカルサイエンスリエゾン部 部長/ メディカルアフェアーズ委 員会WG3
ヤンセンファーマ株式会社/ 米国研究製薬工業協会
研究開発・メディカルアフェアー ズ統括本部バイオ医薬品領域本 部自己免疫疾患領域部長/メディ カルアフェアーズリード/ メディ カルアフェアーズ委員会WG3
日本イーライリリー株式会社/ 米国研究製薬工業協会
お問い合わせはpcampa@medicalaffairs.org までご連絡下さい。
